{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-265804","form_type":"8-K","ticker":"SLDB","cik":"0001707502","company_name":"Solid Biosciences Inc.","filed_at":"2026-06-10T20:05:16+00:00","discovered_at":"2026-06-10T20:06:00.365264+00:00","generated_at":"2026-06-10T20:11:24.692255+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Solid Biosciences shareholders approve doubling of authorized common stock to 480M","bullets":["Approved charter amendment increasing authorized common shares from 240M to 480M; filed June 10, 2026.","Elected Class II directors Clare Kahn, Adam Stone, and Lynne Sullivan with overwhelming votes (73M+ each).","Ratified PricewaterhouseCoopers as independent auditor for FY2026 with 86.4M votes for, 70K against.","Advisory say-on-pay passed with 72.6M votes for and 6.2M against; broker non-votes 7.7M."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-265804","json":"https://secwatch.observer/filing/0001193125-26-265804.json","markdown":"https://secwatch.observer/filing/0001193125-26-265804.md","text":"https://secwatch.observer/filing/0001193125-26-265804.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/0001193125-26-265804-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/sldb-20260610.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T20:11:24.692255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2bd9f71b6742d44169c76916d1717760df2c38d8","claim":"Solid Biosciences Inc. shareholders approved Amendment to Certificate of Incorporation to increase authorized common stock from 240,000,000 to 480,000,000 at the 2026-06-10 meeting.","evidence_excerpt":"The Company’s stockholders approved an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company’s common stock from 240,000,000 to 480,000,000 (the “Share Increase Amendment”).","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/0001193125-26-265804-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"352460afc30ad1de91a917ba3fd6684c3b9b7771","claim":"Solid Biosciences Inc. shareholders approved Ratification of Ilan Ganot as a Class I director (advisory) at the 2026-06-10 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of Ilan Ganot, on an advisory basis, as a Class I director to serve until the 2028 Annual Meeting of Stockholders.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/0001193125-26-265804-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"781205a23d33527f33727abdfa0714fed8b0d0a7","claim":"Solid Biosciences Inc. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2026-06-10 meeting.","evidence_excerpt":"The Company’s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/0001193125-26-265804-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"d06f7ec05c982c375ec73218207fc3ccc15ed551","claim":"Solid Biosciences Inc. shareholders approved Election of Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors at the 2026-06-10 meeting.","evidence_excerpt":"The Company’s stockholders elected Clare Kahn, Adam Stone and Lynne Sullivan as Class II directors to serve until the 2029 Annual Meeting of Stockholders, each director to hold office until his or her successor has been duly appointed and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/0001193125-26-265804-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"},{"claim_id":"eeacc9b0a2cf8bd5fa3847be9529c6e01bf48805","claim":"Solid Biosciences Inc. shareholders approved Non-binding advisory vote on compensation paid to named executive officers at the 2026-06-10 meeting.","evidence_excerpt":"The Company’s stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1707502/000119312526265804/0001193125-26-265804-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}